Human and bovine respiratory syncytial virus vaccine research and development

Comparative Immunology, Microbiology and Infectious Diseases

Volumn 31, Issue 2-3, 2008, Pages 191-225

  Meyer, Gilles ^a   Deplanche, Martine ^a   Schelcher, François ^a  

^a IHAP   (France)

Author keywords

Respiratory syncytial virus; RSV; Vaccine

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN; DENDRITIC CELL VACCINE; DNA VACCINE; GAMMA INTERFERON; GENOMIC RNA; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; INACTIVATED VIRUS VACCINE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 5; LIVE VACCINE; PLACEBO; PROTEIN M2; RECOMBINANT VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; SUBUNIT VACCINE; UNINDEXED DRUG; VIRUS FUSION PROTEIN; VIRUS GLYCOPROTEIN; VIRUS RNA;

ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; DNA IMMUNIZATION; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EOSINOPHILIA; GENETIC ENGINEERING; HIGH RISK POPULATION; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; INFECTION RISK; NONHUMAN; PREVALENCE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; TH1 CELL; UNSPECIFIED SIDE EFFECT; VACCINATION; VACCINE PRODUCTION; VIRAL RESPIRATORY TRACT INFECTION; VIRUS ATTENUATION; VIRUS IMMUNITY; VIRUS PATHOGENESIS;

ANIMALS; CATTLE; HUMANS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, BOVINE; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VIRAL VACCINES;

ANIMALIA; BOVINE RESPIRATORY SYNCYTIAL VIRUS; HYDRANGEA RINGSPOT VIRUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 40149098584     PISSN: 01479571     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cimid.2007.07.008     Document Type: Article

References (250)

1. Glezen W.P., Taber L.H., Frank A.L., and Kasel J.A. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 140 6 (1986) 543-546
2. Henrickson K.J., Hoover S., Kehl K.S., and Hua W. National disease burden of respiratory viruses detected in children by polymerase chain reaction. Pediatr Infect Dis J 23 1 Suppl (2004) S11-S18
3. Shay D.K., Holman R.C., Newman R.D., Liu L.L., Stout J.W., and Anderson L.J. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 282 15 (1999) 1440-1446
4. Simoes E.A., and Carbonell-Estrany X. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries. Pediatr Infect Dis J 22 2 Suppl (2003) S13-S18 [discussion S18-20]
5. Silvestri M., Sabatini F., Defilippi A.C., and Rossi G.A. The wheezy infant-immunological and molecular considerations. Paediatr Respir Rev 5 Suppl A (2004) S81-S87
6. Stein R.T., Sherrill D., Morgan W.J., Holberg C.J., Halonen M., Taussig L.M., et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 354 9178 (1999) 541-545
7. Sigurs N. Epidemiologic and clinical evidence of a respiratory syncytial virus-reactive airway disease link. Am J Respir Crit Care Med 163 3 Pt 2 (2001) S2-S6
8. Noble V., Murray M., Webb M.S., Alexander J., Swarbrick A.S., and Milner A.D. Respiratory status and allergy nine to 10 years after acute bronchiolitis. Arch Dis Child 76 4 (1997) 315-319
9. Peebles Jr. R.S. Viral infections, atopy, and asthma: is there a causal relationship?. J Allergy Clin Immunol 113 1 Suppl (2004) S15-S18
10. Falsey A.R., and Walsh E.E. Respiratory syncytial virus infection in adults. Clin Microbiol Rev 13 3 (2000) 371-384
11. Walsh E.E., Falsey A.R., and Hennessey P.A. Respiratory syncytial and other virus infections in persons with chronic cardiopulmonary disease. Am J Respir Crit Care Med 160 3 (1999) 791-795
12. Raboni S.M., Nogueira M.B., Tsuchiya L.R., Takahashi G.A., Pereira L.A., Pasquini R., et al. Respiratory tract viral infections in bone marrow transplant patients. Transplantation 76 1 (2003) 142-146
13. Hassan I.A., Chopra R., Swindell R., and Mutton K.J. Respiratory viral infections after bone marrow/peripheral stem-cell transplantation: the Christie hospital experience. Bone Marrow Transplant 32 1 (2003) 73-77
14. Elvander M. Severe respiratory disease in dairy cow caused by infection with bovine respiratory syncytial virus. Vet Rec (1996) 101-105
15. Hagglund S., Svensson C., Emanuelson U., Valarcher J.F., and Alenius S. Dynamics of virus infections involved in the bovine respiratory disease complex in Swedish dairy herds. Vet J 172 2 (2006) 320-328
16. Stott E.J., Thomas L.H., Collins A.P., Crouch S., Jebbett J., Smith G.S., et al. A survey of virus infections of the respiratory tract of cattle and their association with disease. J Hyg (Lond) 85 2 (1980) 257-270
17. Kimman T.G., Zimmer G.M., Westenbrink F., Mars J., and van Leeuwen E. Epidemiological study of bovine respiratory syncytial virus infections in calves: influence of maternal antibodies on the outcome of disease. Vet Rec 123 4 (1988) 104-109
18. Baker J.C., Ames T.R., and Markham R.J. Seroepizootiologic study of bovine respiratory syncytial virus in a dairy herd. Am J Vet Res 47 2 (1986) 240-245
19. Uttenthal A., Jensen N.P., and Blom J.Y. Viral aetiology of enzootic pneumonia in Danish dairy herds: diagnostic tools and epidemiology. Vet Rec 139 5 (1996) 114-117
20. Schelcher F., Salat O., Bezille P., and Espinasse J. Approche séroépidémiologique des troubles respiratoires épizootiques des "veaux d'Aveyron": rôle du virus respiratoire syncytial. Rev Méd Vét 141 2 (1990) 117-123
21. Caldow G.L., Edwards S., Nixon P., and Peters A.R. Associations between viral infection and respiratory disease in young beef bulls. Vet Rec 122 22 (1988) 529-531
22. Collins P.L., Chanock R.M., and Murphy B.R. Respiratory syncytial virus (2001), Lippincott Williams and Wilkins, Philadelphia
23. Viuff B., Tjornehoj K., Larsen L.E., Rontved C.M., Uttenthal A., Ronsholt L., et al. Replication and clearance of respiratory syncytial virus: apoptosis is an important pathway of virus clearance after experimental infection with bovine respiratory syncytial virus. Am J Pathol 161 6 (2002) 2195-2207
24. Viuff B., Uttenthal A., Tegtmeier C., and Alexandersen S. Sites of replication of bovine respiratory syncytial virus in naturally infected calves as determined by in situ hybridization. Vet Pathol 33 4 (1996) 383-390
25. Zhang L., Peeples M.E., Boucher R.C., Collins P.L., and Pickles R.J. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol 76 11 (2002) 5654-5666
26. Tripp R.A. Pathogenesis of respiratory syncytial virus infection. Viral Immunol 17 2 (2004) 165-181
27. Openshaw P.J., and Tregoning J.S. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev 18 3 (2005) 541-555
28. Durbin J.E., and Durbin R.K. Respiratory syncytial virus-induced immunoprotection and immunopathology. Viral Immunol 17 3 (2004) 370-380
29. Krishnan S., Halonen M., and Welliver R.C. Innate immune responses in respiratory syncytial virus infections. Viral Immunol 17 2 (2004) 220-233
30. Valarcher J.F., and Taylor G. Bovine respiratory syncytial virus infection. Vet Res 38 2 (2007) 153-180
31. de Waal L., Koopman L.P., van Benten I.J., Brandenburg A.H., Mulder P.G., de Swart R.L., et al. Moderate local and systemic respiratory syncytial virus-specific T-cell responses upon mild or subclinical RSV infection. J Med Virol 70 2 (2003) 309-318
32. Cannon M.J., Openshaw P.J., and Askonas B.A. Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J Exp Med 168 3 (1988) 1163-1168
33. Graham B.S., Bunton L.A., Rowland J., Wright P.F., and Karzon D.T. Respiratory syncytial virus infection in anti-mu-treated mice. J Virol 65 9 (1991) 4936-4942
34. Goulder P.J., Lechner F., Klenerman P., McIntosh K., and Walker B.D. Characterization of a novel respiratory syncytial virus-specific human cytotoxic T-lymphocyte epitope. J Virol 74 16 (2000) 7694-7697
35. Rock M.T., and Crowe Jr. J.E. Identification of a novel human leucocyte antigen-A*01-restricted cytotoxic T-lymphocyte epitope in the respiratory syncytial virus fusion protein. Immunology 108 4 (2003) 474-480
36. Venter M., Rock M., Puren A.J., Tiemessen C.T., and Crowe Jr. J.E. Respiratory syncytial virus nucleoprotein-specific cytotoxic T-cell epitopes in a South African population of diverse HLA types are conserved in circulating field strains. J Virol 77 13 (2003) 7319-7329
37. Johnstone C., de Leon P., Medina F., Melero J.A., Garcia-Barreno B., and Del Val M. Shifting immunodominance pattern of two cytotoxic T-lymphocyte epitopes in the F glycoprotein of the long strain of respiratory syncytial virus. J Gen Virol 85 Pt 11 (2004) 3229-3238
38. Heidema J., de Bree G.J., De Graaff P.M., van Maren W.W., Hoogerhout P., Out T.A., et al. Human CD8(+) T cell responses against five newly identified respiratory syncytial virus-derived epitopes. J Gen Virol 85 Pt 8 (2004) 2365-2374
39. de Waal L., Yuksel S., Brandenburg A.H., Langedijk J.P., Sintnicolaas K., Verjans G.M., et al. Identification of a common HLA-DP4-restricted T-cell epitope in the conserved region of the respiratory syncytial virus G protein. J Virol 78 4 (2004) 1775-1781
40. Rutigliano J.A., Rock M.T., Johnson A.K., Crowe Jr. J.E., and Graham B.S. Identification of an H-2D(b)-restricted CD8+ cytotoxic T lymphocyte epitope in the matrix protein of respiratory syncytial virus. Virology 337 2 (2005) 335-343
41. Lukens M.V., Claassen E.A., de Graaff P.M., van Dijk M.E., Hoogerhout P., Toebes M., et al. Characterization of the CD8+ T cell responses directed against respiratory syncytial virus during primary and secondary infection in C57BL/6 mice. Virology 352 1 (2006) 157-168
42. Lee S., Miller S.A., Wright D.W., Rock M.T., and Crowe Jr. J.E. Tissue-specific regulation of CD8+ T-lymphocyte immunodominance in respiratory syncytial virus infection. J Virol 81 5 (2007) 2349-2358
43. de Waal L., Suzer Y., Wyatt L.S., Sintnicolaas K., Sutter G., Moss B., et al. T cell responses to respiratory syncytial virus fusion and attachment proteins in human peripheral blood mononuclear cells. Viral Immunol 19 4 (2006) 669-678
44. Openshaw P.J., Anderson K., Wertz G.W., and Askonas B.A. The 22,000-kilodalton protein of respiratory syncytial virus is a major target for Kd-restricted cytotoxic T lymphocytes from mice primed by infection. J Virol 64 4 (1990) 1683-1689
45. van Bleek G.M., Poelen M.C., van der Most R., Brugghe H.F., Timmermans H.A., Boog C.J., et al. Identification of immunodominant epitopes derived from the respiratory syncytial virus fusion protein that are recognized by human CD4T cells. J Virol 77 2 (2003) 980-988
46. Boelen A., Kwakkel J., Barends M., de Rond L., Dormans J., and Kimman T. Effect of lack of Interleukin-4, Interleukin-12, Interleukin-18, or the Interferon-gamma receptor on virus replication, cytokine response, and lung pathology during respiratory syncytial virus infection in mice. J Med Virol 66 4 (2002) 552-560
47. Spender L.C., Hussell T., and Openshaw P.J. Abundant IFN-gamma production by local T cells in respiratory syncytial virus-induced eosinophilic lung disease. J Gen Virol 79 Pt 7 (1998) 1751-1758
48. Hussell T., Baldwin C.J., O'Garra A., and Openshaw P.J. CD8+ T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection. Eur J Immunol 27 12 (1997) 3341-3349
49. Durbin J.E., Johnson T.R., Durbin R.K., Mertz S.E., Morotti R.A., Peebles R.S., et al. The role of IFN in respiratory syncytial virus pathogenesis. J Immunol 168 6 (2002) 2944-2952
50. Cherrie A.H., Anderson K., Wertz G.W., and Openshaw P.J. Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22 K, and 1b proteins of respiratory syncytial virus. J Virol 66 4 (1992) 2102-2110
51. Bangham C.R., and McMichael A.J. Specific human cytotoxic T cells recognize B-cell lines persistently infected with respiratory syncytial virus. Proc Natl Acad Sci USA 83 23 (1986) 9183-9187
52. Gaddum R.M., Cook R.S., Furze J.M., Ellis S.A., and Taylor G. Recognition of bovine respiratory syncytial virus proteins by bovine CD8+ T lymphocytes. Immunology 108 2 (2003) 220-229
53. Taylor G., Thomas L.H., Furze J.M., Cook R.S., Wyld S.G., Lerch R., et al. Recombinant vaccinia viruses expressing the F, G or N, but not the M2, protein of bovine respiratory syncytial virus (BRSV) induce resistance to BRSV challenge in the calf and protect against the development of pneumonic lesions. J Gen Virol 78 Pt 12 (1997) 3195-3206
54. Nicholas J.A., Rubino K.L., Levely M.E., Adams E.G., and Collins P.L. Cytolytic T-lymphocyte responses to respiratory syncytial virus: effector cell phenotype and target proteins. J Virol 64 9 (1990) 4232-4241
55. Graham B.S., Rutigliano J.A., and Johnson T.R. Respiratory syncytial virus immunobiology and pathogenesis. Virology 297 1 (2002) 1-7
56. Bukreyev A., Serra M.E., Laham F.R., Melendi G.A., Kleeberger S.R., Collins P.L., et al. The cysteine-rich region and secreted form of the attachment G glycoprotein of respiratory syncytial virus enhance the cytotoxic T-lymphocyte response despite lacking major histocompatibility complex class I-restricted epitopes. J Virol 80 12 (2006) 5854-5861
57. de Graaff P.M., Heidema J., Poelen M.C., van Dijk M.E., Lukens M.V., van Gestel S.P., et al. HLA-DP4 presents an immunodominant peptide from the RSV G protein to CD4 T cells. Virology 326 2 (2004) 220-230
58. Antonis A.F., Claassen E.A., Hensen E.J., de Groot R.J., de Groot-Mijnes J.D., Schrijver R.S., et al. Kinetics of antiviral CD8T cell responses during primary and post-vaccination secondary bovine respiratory syncytial virus infection. Vaccine 24 10 (2006) 1551-1561
59. Chang J., Srikiatkhachorn A., and Braciale T.J. Visualization and characterization of respiratory syncytial virus F-specific CD8(+) T cells during experimental virus infection. J Immunol 167 8 (2001) 4254-4260
60. Rueda P., Delgado T., Portela A., Melero J.A., and Garcia-Barreno B. Premature stop codons in the G glycoprotein of human respiratory syncytial viruses resistant to neutralization by monoclonal antibodies. J Virol 65 6 (1991) 3374-3378
61. Rueda P., Palomo C., Garcia-Barreno B., and Melero J.A. The three C-terminal residues of human respiratory syncytial virus G glycoprotein (long strain) are essential for integrity of multiple epitopes distinguishable by antiidiotypic antibodies. Viral Immunol 8 1 (1995) 37-46
62. Sullender W. Antigenic analysis of chimeric and truncated G proteins of respiratory syncytial virus. Virology 209 1 (1995) 70-79
63. Melero J.A., Garcia-Barreno B., Martinez I., Pringle C.R., and Cane P.A. Antigenic structure, evolution and immunobiology of human respiratory syncytial virus attachment (G) protein. J Gen Virol 78 Pt 10 (1997) 2411-2418
64. Langedijk J.P., Meloen R.H., Taylor G., Furze J.M., and van Oirschot J.T. Antigenic structure of the central conserved region of protein G of bovine respiratory syncytial virus. J Virol 71 5 (1997) 4055-4061
65. Langedijk J.P., Schaaper W.M., Meloen R.H., and van Oirschot J.T. Proposed three-dimensional model for the attachment protein G of respiratory syncytial virus. J Gen Virol 77 Pt 6 (1996) 1249-1257
66. Prozzi D., Walravens K., Langedijk J.P., Daus F., Kramps J.A., and Letesson J.J. Antigenic and molecular analyses of the variability of bovine respiratory syncytial virus G glycoprotein. J Gen Virol 78 Pt 2 (1997) 359-366
67. Walsh E.E., Falsey A.R., and Sullender W.M. Monoclonal antibody neutralization escape mutants of respiratory syncytial virus with unique alterations in the attachment (G) protein. J Gen Virol 79 Pt 3 (1998) 479-487
68. Martinez I., Dopazo J., and Melero J.A. Antigenic structure of the human respiratory syncytial virus G glycoprotein and relevance of hypermutation events for the generation of antigenic variants. J Gen Virol 78 Pt 10 (1997) 2419-2429
69. Marsh R., Connor A., Gias E., and Toms G.L. Increased susceptibility of human respiratory syncytial virus to neutralization by anti-fusion protein antibodies on adaptation to replication in cell culture. J Med Virol 79 6 (2007) 829-837
70. Crowe Jr. J.E. Influence of maternal antibodies on neonatal immunization against respiratory viruses. Clin Infect Dis 33 10 (2001) 1720-1727
71. Singleton R., Etchart N., Hou S., and Hyland L. Inability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responses. J Virol 77 21 (2003) 11303-11311
72. Braciale T.J. Respiratory syncytial virus and T cells: interplay between the virus and the host adaptive immune system. Proc Am Thorac Soc 2 2 (2005) 141-146
73. Vallbracht S., Unsold H., and Ehl S. Functional impairment of cytotoxic T cells in the lung airways following respiratory virus infections. Eur J Immunol 36 6 (2006) 1434-1442
74. Chi B., Dickensheets H.L., Spann K.M., Alston M.A., Luongo C., Dumoutier L., et al. Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus. J Virol 80 10 (2006) 5032-5040
75. de Graaff P.M., de Jong E.C., van Capel T.M., van Dijk M.E., Roholl P.J., Boes J., et al. Respiratory syncytial virus infection of monocyte-derived dendritic cells decreases their capacity to activate CD4T cells. J Immunol 175 9 (2005) 5904-5911
76. Jones A., Morton I., Hobson L., Evans G.S., and Everard M.L. Differentiation and immune function of human dendritic cells following infection by respiratory syncytial virus. Clin Exp Immunol 143 3 (2006) 513-522
77. Brandenburg A.H., Neijens H.J., and Osterhaus A.D. Pathogenesis of RSV lower respiratory tract infection: implications for vaccine development. Vaccine 19 20-22 (2001) 2769-2782
78. Whitehead S.S., Juhasz K., Firestone C.Y., Collins P.L., and Murphy B.R. Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J Virol 72 5 (1998) 4467-4471
79. Collins P.L., Purcell R.H., London W.T., Lawrence L.A., Chanock R.M., and Murphy B.R. Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus. Vaccine 8 2 (1990) 164-168
80. Belknap E.B., Ciszewski D.K., and Baker J.C. Experimental respiratory syncytial virus infection in calves and lambs. J Vet Diagn Invest 7 2 (1995) 285-298
81. Larsen L.E. Bovine respiratory syncytial virus (BRSV): a review. Acta Vet Scand 41 1 (2000) 1-24
82. West K., Petrie L., Haines D.M., Konoby C., Clark E.G., Martin K., et al. The effect of formalin-inactivated vaccine on respiratory disease associated with bovine respiratory syncytial virus infection in calves. Vaccine 17 7-8 (1999) 809-820
83. Tjornehoj K., Uttenthal A., Viuff B., Larsen L.E., Rontved C., and Ronsholt L. An experimental infection model for reproduction of calf pneumonia with bovine respiratory syncytial virus (BRSV) based on one combined exposure of calves. Res Vet Sci 74 1 (2003) 55-65
84. Boxus M., Tignon M., Roels S., Toussaint J.F., Walravens K., Benoit M.A., et al. DNA immunization with plasmids encoding fusion and nucleocapsid proteins of BRSV induces a strong cell-mediated immunity and protects calves against challenge. J Virol 81 (2007) 6879-6889
85. Delespesse G., Yang L.P., Ohshima Y., Demeure C., Shu U., Byun D.G., et al. Maturation of human neonatal CD4+ and CD8+ T lymphocytes into Th1/Th2 effectors. Vaccine 16 14-15 (1998) 1415-1419
86. Siegrist C.A. Neonatal and early life vaccinology. Vaccine 19 25-26 (2001) 3331-3346
87. Crowe Jr. J.E., Firestone C.Y., and Murphy B.R. Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines. J Immunol 167 7 (2001) 3910-3918
88. Kimman T.G., Westenbrink F., Schreuder B.E., and Straver P.J. Local and systemic antibody response to bovine respiratory syncytial virus infection and reinfection in calves with and without maternal antibodies. J Clin Microbiol 25 6 (1987) 1097-1106
89. Murphy B.R., Prince G.A., Collins P.L., Hildreth S.W., and Paradiso P.R. Effect of passive antibody on the immune response of cotton rats to purified F and G glycoproteins of respiratory syncytial virus (RSV). Vaccine 9 3 (1991) 185-189
90. Murphy B.R., Olmsted R.A., Collins P.L., Chanock R.M., and Prince G.A. Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses. J Virol 62 10 (1988) 3907-3910
91. Durbin A.P., Cho C.J., Elkins W.R., Wyatt L.S., Moss B., and Murphy B.R. Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies. J Infect Dis 179 6 (1999) 1345-1351
92. Murphy B.R., Sotnikov A., Paradiso P.R., and Hildreth S.Wa. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease. Vaccine 7 (1989) 533-540
93. Kimman T.G., Westenbrink F., and Straver P.J. Priming for local and systemic antibody memory responses to bovine respiratory syncytial virus: effect of amount of virus, virus replication, route of administration and maternal antibodies. Vet Immunol Immunopathol 22 2 (1989) 145-160
94. Ellis J.A., Hassard L.E., Cortese V.S., and Morley P.S. Effects of perinatal vaccination on humoral and cellular immune responses in cows and young calves. J Am Vet Med Assoc 208 3 (1996) 393-400
95. Cane P.A. Molecular epidemiology of respiratory syncytial virus. Rev Med Virol 11 2 (2001) 103-116
96. Sullender W.M. Respiratory syncytial virus genetic and antigenic diversity. Clin Microbiol Rev 13 1 (2000) 1-15 table of contents
97. Simard C., Nadon F., Seguin C., Thien N.N., Binz H., Basso J., et al. Subgroup specific protection of mice from respiratory syncytial virus infection with peptides encompassing the amino acid region 174-187 from the G glycoprotein: the role of cysteinyl residues in protection. Vaccine 15 4 (1997) 423-432
98. Trudel M., Nadon F., Seguin C., and Binz H. Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein. Virology 185 2 (1991) 749-757
99. Sullender W.M., Anderson K., and Wertz G.W. The respiratory syncytial virus subgroup B attachment glycoprotein: analysis of sequence, expression from a recombinant vector, and evaluation as an immunogen against homologous and heterologous subgroup virus challenge. Virology 178 1 (1990) 195-203
100. Furze J., Wertz G., Lerch R., and Taylor G. Antigenic heterogeneity of the attachment protein of bovine respiratory syncytial virus. J Gen Virol 75 Pt 2 (1994) 363-370
101. Schrijver R.S., Daus F., Kramps J.A., Langedijk J.P., Buijs R., Middel W.G., et al. Subgrouping of bovine respiratory syncytial virus strains detected in lung tissue. Vet Microbiol 53 3-4 (1996) 253-260
102. Larsen L.E., Uttenthal A., Arctander P., Tjornehoj K., et al. Serological and genetic characterisation of bovine respiratory syncytial virus (BRSV) indicates that Danish isolates belong to the intermediate subgroup: no evidence of a selective effect on the variability of G protein nucleotide sequence by prior cell culture adaptation and passages in cell culture or calves. Vet Microbiol 62 (1998) 265-279
103. Nettleton P.F., Gilray J.A., Caldow G., Gidlow J.R., Durkovic B., and Vilcek S. Recent isolates of bovine respiratory syncytial virus from Britain are more closely related to isolates from USA than to earlier British and current mainland European isolates. J Vet Med B Infect Dis Vet Public Health 50 4 (2003) 196-199
104. Valarcher J.F., Schelcher F., and Bourhy H. Evolution of bovine respiratory syncytial virus. J Virol 74 22 (2000) 10714-10728
105. Furze J.M., Roberts S.R., Wertz G.W., and Taylor G. Antigenically distinct G glycoproteins of BRSV strains share a high degree of genetic homogeneity. Virology 231 1 (1997) 48-58
106. Deplanche M., Lemaire M., Mirandette C., Bonnet M., Schelcher F., and Meyer G. In vivo evidence for quasispecies distributions in the bovine respiratory syncytial virus genome. J Gen Virol 88 Pt 4 (2007) 1260-1265
107. Zhao X., Chen F.P., and Sullender W.M. Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats. Virology 318 2 (2004) 608-612
108. Zhao X., and Sullender W.M. In vivo selection of respiratory syncytial viruses resistant to palivizumab. J Virol 79 7 (2005) 3962-3968
109. Huang Y., and Anderson R. A single amino acid substitution in a recombinant G protein vaccine drastically curtails protective immunity against respiratory syncytial virus (RSV). Vaccine 21 19-20 (2003) 2500-2505
110. Dudas R.A., and Karron R.A. Respiratory syncytial virus vaccines. Clin Microbiol Rev 11 3 (1998) 430-439
111. Openshaw P.J., Culley F.J., and Olszewska W. Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine 20 Suppl 1 (2001) S27-S31
112. Graham B.S., Henderson G.S., Tang Y.W., Lu X., Neuzil K.M., and Colley D.G. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol 151 4 (1993) 2032-2040
113. Connors M., Giese N.A., Kulkarni A.B., Firestone C.Y., Morse III H.C., and Murphy B.R. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol 68 8 (1994) 5321-5325
114. Connors M., Collins P.L., Firestone C.Y., Sotnikov A.V., Waitze A., Davis A.R., et al. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia-RSV recombinants or RSV. Vaccine 10 7 (1992) 475-484
115. Waris M.E., Tsou C., Erdman D.D., Zaki S.R., and Anderson L.J. Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol 70 5 (1996) 2852-2860
116. Aung S., Tang Y.W., and Graham B.S. Interleukin-4 diminishes CD8(+) respiratory syncytial virus-specific cytotoxic T-lymphocyte activity in vivo. J Virol 73 11 (1999) 8944-8949
117. Sparer T.E., Matthews S., Hussell T., Rae A.J., Garcia-Barreno B., Melero J.A., et al. Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. J Exp Med 187 11 (1998) 1921-1926
118. Srikiatkhachorn A., and Braciale T.J. Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection. J Virol 71 1 (1997) 678-685
119. Polack F.P., Teng M.N., Collins P.L., Prince G.A., Exner M., Regele H., et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 196 6 (2002) 859-865
120. Johnson T.R., Teng M.N., Collins P.L., and Graham B.S. Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV. J Virol 78 11 (2004) 6024-6032
121. De Swart R.L., Kuiken T., Timmerman H.H., Amerongen Gv G., Van Den Hoogen B.G., Vos H.W., et al. Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection. J Virol 76 22 (2002) 11561-11569
122. Ponnuraj E.M., Hayward A.R., Raj A., Wilson H., and Simoes E.A. Increased replication of respiratory syncytial virus (RSV) in pulmonary infiltrates is associated with enhanced histopathological disease in bonnet monkeys (Macaca radiata) pre-immunized with a formalin-inactivated RSV vaccine. J Gen Virol 82 Pt 11 (2001) 2663-2674
123. Gershwin L.J., Schelegle E.S., Gunther R.A., Anderson M.L., Woolums A.R., Larochelle D.R., et al. A bovine model of vaccine enhanced respiratory syncytial virus pathophysiology. Vaccine 16 11-12 (1998) 1225-1236
124. Antonis A.F., Schrijver R.S., Daus F., Steverink P.J., Stockhofe N., Hensen E.J., et al. Vaccine-induced immunopathology during bovine respiratory syncytial virus infection: exploring the parameters of pathogenesis. J Virol 77 22 (2003) 12067-12073
125. Kalina W.V., and Gershwin L.J. Progress in defining the role of RSV in allergy and asthma: from clinical observations to animal models. Clin Dev Immunol 11 2 (2004) 113-119
126. Kimman T.G., Daha M.R., Brinkhof J.M., and Westenbrink F. Activation of complement by bovine respiratory syncytial virus-infected cells. Vet Immunol Immunopathol 21 3-4 (1989) 311-325
127. Ellis J., West K., Konoby C., Leard T., Gallo G., Conlon J., et al. Efficacy of an inactivated respiratory syncytial virus vaccine in calves. J Am Vet Med Assoc 218 12 (2001) 1973-1980
128. Larsen L.E., Tegtmeier C., and Pedersen E. Bovine respiratory syncytial virus (BRSV) pneumonia in beef calf herds despite vaccination. Acta Vet Scand 42 1 (2001) 113-121
129. Schreiber P., Matheise J.P., Dessy F., Heimann M., Letesson J.J., Coppe P., et al. High mortality rate associated with bovine respiratory syncytial virus (BRSV) infection in Belgian white blue calves previously vaccinated with an inactivated BRSV vaccine. J Vet Med B Infect Dis Vet Public Health 47 7 (2000) 535-550
130. Waris M.E., Tsou C., Erdman D.D., Day D.B., and Anderson L.J. Priming with live respiratory syncytial virus (RSV) prevents the enhanced pulmonary inflammatory response seen after RSV challenge in BALB/c mice immunized with formalin-inactivated RSV. J Virol 71 9 (1997) 6935-6939
131. Neuzil K.M., Johnson J.E., Tang Y.W., Prieels J.P., Slaoui M., Gar N., et al. Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine. Vaccine 15 5 (1997) 525-532
132. Ellis J.A., West K.H., Waldner C., and Rhodes C. Efficacy of a saponin-adjuvanted inactivated respiratory syncytial virus vaccine in calves. Can Vet J 46 2 (2005) 155-162
133. Brideau R.J., and Wathen M.W. A chimeric glycoprotein of human respiratory syncytial virus termed FG induces T-cell mediated immunity in mice. Vaccine 9 12 (1991) 863-864
134. Crowe Jr. J.E., Bui P.T., Siber G.R., Elkins W.R., Chanock R.M., and Murphy B.R. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine 13 9 (1995) 847-855
135. Walsh E.E., Hall C.B., Briselli M., Brandriss M.W., and Schlesinger J.J. Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection. J Infect Dis 155 6 (1987) 1198-1204
136. Wathen M.W., Kakuk T.J., Brideau R.J., Hausknecht E.C., Cole S.L., and Zaya R.M. Vaccination of cotton rats with a chimeric FG glycoprotein of human respiratory syncytial virus induces minimal pulmonary pathology on challenge. J Infect Dis 163 3 (1991) 477-482
137. Hancock G.E., Speelman D.J., Frenchick P.J., Mineo-Kuhn M.M., Baggs R.B., and Hahn D.J. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection. Vaccine 13 4 (1995) 391-400
138. Walsh E.E. Humoral, mucosal, and cellular immune response to topical immunization with a subunit respiratory syncytial virus vaccine. J Infect Dis 170 2 (1994) 345-350
139. Murphy B.R., Sotnikov A.V., Lawrence L.A., Banks S.M., and Prince G.A. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization [see comments]. Vaccine 8 5 (1990) 497-502
140. Falsey A.R., and Walsh E.E. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine 15 10 (1997) 1130-1132
141. Falsey A.R., and Walsh E.E. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine 14 13 (1996) 1214-1218
142. Munoz F.M., Piedra P.A., and Glezen W.P. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 21 24 (2003) 3465-3467
143. Belshe R.B., Anderson E.L., and Walsh E.E. Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children. J Infect Dis 168 4 (1993) 1024-1029
144. Tristram D.A., Welliver R.C., Mohar C.K., Hogerman D.A., et al. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J Infect Dis 167 (1993) 191-195
145. Piedra P.A., Grace S., Jewell A., Spinelli S., Bunting D., Hogerman D.A., et al. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr Infect Dis J 15 1 (1996) 23-31
146. Groothuis J.R., King S.J., Hogerman D.A., Paradiso P.R., and Simoes E.A. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J Infect Dis 177 2 (1998) 467-469
147. Piedra P.A., Cron S.G., Jewell A., Hamblett N., McBride R., Palacio M.A., et al. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. Vaccine 21 19-20 (2003) 2448-2460
148. Power U.F., Nguyen T.N., Rietveld E., de Swart R.L., Groen J., Osterhaus A.D., et al. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J Infect Dis 184 11 (2001) 1456-1460
149. Plotnicky-Gilquin H., Huss T., Aubry J.P., Haeuw J.F., Beck A., Bonnefoy J.Y., et al. Absence of lung immunopathology following respiratory syncytial virus (RSV) challenge in mice immunized with a recombinant RSV G protein fragment. Virology 258 1 (1999) 128-140
150. Plotnicky H., Siegrist C.A., Aubry J.P., Bonnefoy J.Y., Corvaia N., Nguyen T.N., et al. Enhanced pulmonary immunopathology following neonatal priming with formalin-inactivated respiratory syncytial virus but not with the BBG2NA vaccine candidate. Vaccine 21 19-20 (2003) 2651-2660
151. Brandt C., Power U.F., Plotnicky-Gilquin H., Huss T., Nguyen T., Lambert P.H., et al. Protective immunity against respiratory syncytial virus in early life after murine maternal or neonatal vaccination with the recombinant G fusion protein BBG2Na. J Infect Dis 176 4 (1997) 884-891
152. Goetsch L., Plotnicky-Gilquin H., Aubry J.P., De-Lys P., Haeuw J.F., Bonnefoy J.Y., et al. BBG2Na an RSV subunit vaccine candidate intramuscularly injected to human confers protection against viral challenge after nasal immunization in mice. Vaccine 19 28-29 (2001) 4036-4042
153. Siegrist C.A., Plotnicky-Gilquin H., Cordova M., Berney M., Bonnefoy J.Y., Nguyen T.N., et al. Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: influence of adjuvants and maternal antibodies. J Infect Dis 179 6 (1999) 1326-1333
154. Power U.F., Plotnicky H., Blaecke A., and Nguyen T.N. The immunogenicity, protective efficacy and safety of BBG2Na, a subunit respiratory syncytial virus (RSV) vaccine candidate, against RSV-B. Vaccine 22 2 (2003) 168-176
155. de Waal L., Power U.F., Yuksel S., van Amerongen G., Nguyen T.N., Niesters H.G., et al. Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge. Vaccine 22 8 (2004) 915-922
156. Kakuk T.J., Soike K., Brideau R.J., Zaya R.M., Cole S.L., Zhang J.Y., et al. A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine. J Infect Dis 167 3 (1993) 553-561
157. Klinguer-Hamour C., Bussat M.C., Plotnicky H., Velin D., Corvaia N., Nguyen T., et al. Synthesis, refolding and protective immune responses of a potential antigen for human respiratory syncytial virus vaccine. J Pept Res 62 1 (2003) 27-36
158. Fan C.F., Zeng R.H., Sun C.Y., Mei X.G., Wang Y.F., and Liu Y. Fusion of DsbA to the N-terminus of CTL chimeric epitope, F/M2:81-95, of respiratory syncytial virus prolongs protein- and virus-specific CTL responses in Balb/c mice. Vaccine 23 22 (2005) 2869-2875
159. Zeng R.H., Gong W., Fan C.F., Wang Y.F., and Mei X.G. Induction of balanced immunity in BALB/c mice by vaccination with a recombinant fusion protein containing a respiratory syncytial virus G protein fragment and a CTL epitope. Vaccine 24 7 (2006) 941-947
160. Oien N.L., Brideau R.J., Walsh E.E., and Wathen M.W. Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit. Vaccine 12 8 (1994) 731-735
161. Tebbey P.W., Unczur C.A., LaPierre N.A., and Hancock G.E. A novel and effective intranasal immunization strategy for respiratory syncytial virus. Viral Immunol 12 1 (1999) 41-45
162. Etchart N., Baaten B., Andersen S.R., Hyland L., Wong S.Y., and Hou S. Intranasal immunisation with inactivated RSV and bacterial adjuvants induces mucosal protection and abrogates eosinophilia upon challenge. Eur J Immunol 36 5 (2006) 1136-1144
163. Klinguer-Hamour C., Libon C., Plotnicky-Gilquin H., Bussat M.C., Revy L., Nguyen T., et al. DDA adjuvant induces a mixed Th1/Th2 immune response when associated with BBG2Na, a respiratory syncytial virus potential vaccine. Vaccine 20 21-22 (2002) 2743-2751
164. Fujihashi K., Koga T., van Ginkel F.W., Hagiwara Y., and McGhee J.R. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 20 19-20 (2002) 2431-2438
165. Howard C.J., Stott E.J., Thomas L.H., Gourlay R.N., and Taylor G. Protection against respiratory disease in calves induced vaccines containing respiratory syncytial virus, parainfluenza type 3 virus Mycoplasma bovis and M dispar. Vet Rec 121 (1987) 372-376
166. Stott E., Thomas L.H., Taylor G., Collins A.P., et al. A comparison of three vaccines against respiratory syncytial virus in calves. J Hyg Camb 93 (1984) 251-261
167. Stott EJ, Thomas LH, Taylor C. Development of a potent inactivated vaccine against respiratory syncytial virus infection of calves. In: Proceedings of the world congress of Buiatrics Society, Dublin, 1986.
168. Hancock G.E., Smith J.D., and Heers K.M. The immunogenicity of subunit vaccines for respiratory syncytial virus after co-formulation with aluminum hydroxide adjuvant and recombinant interleukin-12. Viral Immunol 13 1 (2000) 57-72
169. Hu K.F., Regner M., Siegrist C.A., Lambert P., Chen M., Bengtsson K.L., et al. The immunomodulating properties of human respiratory syncytial virus and immunostimulating complexes containing Quillaja saponin components QH-A, QH-C and ISCOPREP703. FEMS Immunol Med Microbiol 43 2 (2005) 269-276
170. Hagglund S., Hu K.F., Larsen L.E., Hakhverdyan M., Valarcher J.F., Taylor G., et al. Bovine respiratory syncytial virus ISCOMs-protection in the presence of maternal antibodies. Vaccine 23 5 (2004) 646-655
171. Askew D., Chu R.S., Krieg A.M., and Harding C.V. CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms. J Immunol 165 12 (2000) 6889-6895
172. Krieg A.M. The role of CpG motifs in innate immunity. Curr Opin Immunol 12 1 (2000) 35-43
173. Oumouna M., Mapletoft J.W., Karvonen B.C., Babiuk L.A., and van Drunen Littel-van den Hurk S. Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine. J Virol 79 4 (2005) 2024-2032
174. Prince G.A., Mond J.J., Porter D.D., Yim K.C., Lan S.J., and Klinman D.M. Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant. J Virol 77 24 (2003) 13156-13160
175. Mapletoft J.W., Oumouna M., Townsend H.G., Gomis S., Babiuk L.A., and van Drunen Littel-van den Hurk S. Formulation with CpG oligodeoxynucleotides increases cellular immunity and protection induced by vaccination of calves with formalin-inactivated bovine respiratory syncytial virus. Virology 353 2 (2006) 316-323
176. Heath W.R., and Carbone F.R. Cross-presentation in viral immunity and self-tolerance. Nat Rev Immunol 1 2 (2001) 126-134
177. Mottram P.L., Leong D., Crimeen-Irwin B., Gloster S., Xiang S.D., Meanger J., et al. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. Mol Pharm 4 1 (2007) 73-84
178. Mawhinney I.C., and Burrows M.R. Protection against bovine respiratory syncytial virus challenge following a single dose of vaccine in young calves with maternal antibody. Vet Rec 156 5 (2005) 139-143
179. Kerkhofs P., Tignon M., Petry H., Mawhinney I., and Sustronck B. Immune responses to bovine respiratory syncytial virus (BRSV) following use of an inactivated BRSV-PI3-Mannheimia haemolytica vaccine and a modified live BRSV-BVDV vaccine. Vet J 167 2 (2004) 208-210
180. Harmeyer S.S., Murray J., Imrie C., Wiseman A., and Salt J.S. Efficacy of a live bovine respiratory syncytial virus vaccine in seropositive calves. Vet Rec 159 14 (2006) 456-457
181. Ellis J., Gow S., West K., Waldner C., Rhodes C., Mutwiri G., et al. Response of calves to challenge exposure with virulent bovine respiratory syncytial virus following intranasal administration of vaccines formulated for parenteral administration. J Am Vet Med Assoc 230 2 (2007) 233-243
182. Ferguson J.D., Galligan D.T., and Cortese V. Milk production and reproductive performance in dairy cows given bovine respiratory syncytial virus vaccine prior to parturition. J Am Vet Med Assoc 210 12 (1997) 1779-1783
183. Thomson J.R., Nettleton P.F., Greig A., and Barr J. A bovine respiratory virus vaccination trial. Vet Rec 119 18 (1986) 450-453
184. Van Donkersgoed J., Potter A.A., Mollison B., and Harland R.J. The effect of a combined Pasteurella haemolytica and Haemophilus somnus vaccine and a modified-live bovine respiratory syncytial virus vaccine against enzootic pneumonia in young beef calves. Can Vet J 35 4 (1994) 239-241
185. Verhoeff J., and van Nieuwstadt A.P. Prevention of bovine respiratory syncytial virus infection and clinical disease by vaccination. Vet Rec 115 19 (1984) 488-492
186. Buchholz U.J., Granzow H., Schuldt K., Whitehead S.S., Murphy B.R., and Collins P.L. Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine. J Virol 74 3 (2000) 1187-1199
187. Vangeel I, Antonis AF, Fluess M, Riegler L, Peters AR, Harmeyer SS. Efficacy of a modified live intranasal bovine respiratory syncytial virus vaccine in 3-week-old calves experimentally challenged with BRSV. Vet J 2006.
188. Murphy B.R., Hall S.L., Kulkarni A.B., Crowe Jr. J.E., Collins P.L., Connors M., et al. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res 32 1 (1994) 13-36
189. McKay E., Higgins P., Tyrrell D., and Pringle C. Immunogenicity and pathogenicity of temperature-sensitive modified respiratory syncytial virus in adult volunteers. J Med Virol 25 (1988) 411-421
190. Pringle C.R., Filipiuk A.H., Robinson B.S., Watt P.J., Higgins P., and Tyrrell D.A. Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers. Vaccine 11 4 (1993) 473-478
191. McIntosh K., Arbeter A.M., Stahl M.K., Orr I.A., Hodes D.S., and Ellis E.F. Attenuated respiratory syncytial virus vaccines in asthmatic children. Pediatr Res 8 7 (1974) 689-696
192. Wright P.F., Shinozaki T., Fleet W., Sell S.H., Thompson J., and Karzon D.T. Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants. J Pediatr 88 6 (1976) 931-936
193. Crowe Jr. J.E., Bui P.T., London W.T., Davis A.R., Hung P.P., Chanock R.M., et al. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine 12 8 (1994) 691-699
194. Crowe Jr. J.E., Bui P.T., Davis A.R., Chanock R.M., and Murphy B.R. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine 12 9 (1994) 783-790
195. Crowe Jr. J.E., Collins P.L., London W.T., Chanock R.M., and Murphy B.R. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine 11 14 (1993) 1395-1404
196. Karron R.A., Wright P.F., Crowe Jr. J.E., Clements-Mann M.L., Thompson J., Makhene M., et al. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis 176 6 (1997) 1428-1436
197. Gonzalez I.M., Karron R.A., Eichelberger M., Walsh E.E., Delagarza V.W., Bennett R., et al. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults. Vaccine 18 17 (2000) 1763-1772
198. Wright P.F., Karron R.A., Belshe R.B., Thompson J., Crowe Jr. J.E., Boyce T.G., et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 182 5 (2000) 1331-1342
199. Buchholz U.J., Finke S., and Conzelmann K.K. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J Virol 73 1 (1999) 251-259
200. Collins P.L., Whitehead S.S., Bukreyev A., Fearns R., Teng M.N., Juhasz K., et al. Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics. Adv Virus Res 54 (1999) 423-451
201. Karron R.A., Wright P.F., Belshe R.B., Thumar B., Casey R., Newman F., et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 191 7 (2005) 1093-1104
202. Bermingham A., and Collins P.L. The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proc Natl Acad Sci USA 96 20 (1999) 11259-11264
203. Jin H., Zhou H., Cheng X., Tang R., Munoz M., and Nguyen N. Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo. Virology 273 1 (2000) 210-218
204. Karron R.A., Buonagurio D.A., Georgiu A.F., Whitehead S.S., Adamus J.E., Clements-Mann M.L., et al. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc Natl Acad Sci USA 94 25 (1997) 13961-13966
205. Teng M.N., Whitehead S.S., and Collins P.L. Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology 289 2 (2001) 283-296
206. Karger A., Schmidt U., and Buchholz U.J. Recombinant bovine respiratory syncytial virus with deletions of the G or SH genes: G and F proteins bind heparin. J Gen Virol 82 Pt 3 (2001) 631-640
207. Techaarpornkul S., Barretto N., and Peeples M.E. Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene. J Virol 75 15 (2001) 6825-6834
208. Whitehead S.S., Bukreyev A., Teng M.N., Firestone C.Y., St Claire M., Elkins W.R., et al. Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J Virol 73 4 (1999) 3438-3442
209. Maher C.F., Hussell T., Blair E., Ring C.J., and Openshaw P.J. Recombinant respiratory syncytial virus lacking secreted glycoprotein G is attenuated, non-pathogenic but induces protective immunity. Microbes Infect 6 12 (2004) 1049-1055
210. Valarcher J.F., Furze J., Wyld S.G., Cook R., Zimmer G., Herrler G., et al. Bovine respiratory syncytial virus lacking the virokinin or with a mutation in furin cleavage site RA(R/K)R109 induces less pulmonary inflammation without impeding the induction of protective immunity in calves. J Gen Virol 87 Pt 6 (2006) 1659-1667
211. Valarcher J.F., Furze J., Wyld S., Cook R., Conzelmann K.K., and Taylor G. Role of alpha/beta interferons in the attenuation and immunogenicity of recombinant bovine respiratory syncytial viruses lacking NS proteins. J Virol 77 15 (2003) 8426-8439
212. Teng M.N., Whitehead S.S., Bermingham A., St Claire M., Elkins W.R., Murphy B.R., et al. Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J Virol 74 19 (2000) 9317-9321
213. Cheng X., Zhou H., Tang R.S., Munoz M.G., and Jin H. Chimeric subgroup A respiratory syncytial virus with the glycoproteins substituted by those of subgroup B and RSV without the M2-2 gene are attenuated in African green monkeys. Virology 283 1 (2001) 59-68
214. Jin H., Cheng X., Traina-Dorge V.L., Park H.J., Zhou H., Soike K., et al. Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates. Vaccine 21 25-26 (2003) 3647-3652
215. Tripp R.A., Jones L.P., Haynes L.M., Zheng H., Murphy P.M., and Anderson L.J. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2 8 (2001) 732-738
216. Harcourt J.L., Karron R.A., and Tripp R.A. Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis. J Infect Dis 190 11 (2004) 1936-1940
217. Harcourt J., Alvarez R., Jones L.P., Henderson C., Anderson L.J., and Tripp R.A. Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses. J Immunol 176 3 (2006) 1600-1608
218. Haynes L.M., Jones L.P., Barskey A., Anderson L.J., and Tripp R.A. Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. J Virol 77 18 (2003) 9831-9844
219. Tripp R.A., Dakhama A., Jones L.P., Barskey A., Gelfand E.W., and Anderson L.J. The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P. J Virol 77 11 (2003) 6580-6584
220. Li X.Q., Fu Z.F., Alvarez R., Henderson C., and Tripp R.A. Respiratory syncytial virus (RSV) infects neuronal cells and processes that innervate the lung by a process involving RSV G protein. J Virol 80 1 (2006) 537-540
221. Gonzalez-Reyes L., Ruiz-Arguello M.B., Garcia-Barreno B., Calder L., Lopez J.A., Albar J.P., et al. Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion. Proc Natl Acad Sci USA 98 17 (2001) 9859-9864
222. Zimmer G., Budz L., and Herrler G. Proteolytic activation of respiratory syncytial virus fusion protein. Cleavage at two furin consensus sequences. J Biol Chem 276 34 (2001) 31642-31650
223. Zimmer G., Rohn M., McGregor G.P., Schemann M., Conzelmann K.K., and Herrler G. Virokinin, a bioactive peptide of the tachykinin family, is released from the fusion protein of bovine respiratory syncytial virus. J Biol Chem 278 47 (2003) 46854-46861
224. Krempl C., Murphy B.R., and Collins P.L. Recombinant respiratory syncytial virus with the G and F genes shifted to the promoter-proximal positions. J Virol 76 23 (2002) 11931-11942
225. Bukreyev A., Belyakov I.M., Berzofsky J.A., Murphy B.R., and Collins P.L. Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells. J Virol 75 24 (2001) 12128-12140
226. Olszewska W., Suezer Y., Sutter G., and Openshaw P.J. Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins. Vaccine 23 2 (2004) 215-221
227. Crowe J.E.J., Collins P.L., Chanock R.M., and Murphy B.R. Vaccines against respiratory syncytial virus and parainfluenza virus type 3 (1997), Marcel Dekker, New York
228. Antonis AF, van der Most RG, Suezer Y, Stockhofe-Zurwieden N, Daus F, Sutter G, et al. Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge. Vaccine 2007.
229. Karron R.A., Makhene M., Gay K., Wilson M.H., Clements M.L., and Murphy B.R. Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants. Pediatr Infect Dis J 15 8 (1996) 650-654
230. Schmidt A.C., McAuliffe J.M., Huang A., Surman S.R., Bailly J.E., Elkins W.R., et al. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J Virol 74 19 (2000) 8922-8929
231. Schmidt A.C., Wenzke D.R., McAuliffe J.M., St Claire M., Elkins W.R., Murphy B.R., et al. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. J Virol 76 3 (2002) 1089-1099
232. Schmidt A.C., McAuliffe J.M., Murphy B.R., and Collins P.L. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J Virol 75 10 (2001) 4594-4603
233. Tang R.S., Schickli J.H., MacPhail M., Fernandes F., Bicha L., Spaete J., et al. Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3′ proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity. J Virol 77 20 (2003) 10819-10828
234. Tang R.S., MacPhail M., Schickli J.H., Kaur J., Robinson C.L., Lawlor H.A., et al. Parainfluenza virus type 3 expressing the native or soluble fusion (F) protein of respiratory syncytial virus (RSV) confers protection from RSV infection in African green monkeys. J Virol 78 20 (2004) 11198-11207
235. Taylor G., Rijsewijk F.A., Thomas L.H., Wyld S.G., Gaddum R.M., Cook R.S., et al. Resistance to bovine respiratory syncytial virus (BRSV) induced in calves by a recombinant bovine herpesvirus-1 expressing the attachment glycoprotein of BRSV. J Gen Virol 79 Pt 7 (1998) 1759-1767
236. Li X., Sambhara S., Li C.X., Ewasyshyn M., Parrington M., Caterini J., et al. Protection against respiratory syncytial virus infection by DNA immunization. J Exp Med 188 4 (1998) 681-688
237. Manickan E., Yu Z., and Rouse B.T. DNA immunization of neonates induces immunity despite the presence of maternal antibody. J Clin Invest 100 9 (1997) 2371-2375
238. Pertmer T.M., Oran A.E., Moser J.M., Madorin C.A., and Robinson H.L. DNA vaccines for influenza virus: differential effects of maternal antibody on immune responses to hemagglutinin and nucleoprotein. J Virol 74 17 (2000) 7787-7793
239. Polack F.P., Lee S.H., Permar S., Manyara E., Nousari H.G., Jeng Y., et al. Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles. Nat Med 6 7 (2000) 776-781
240. Wang Y., Xiang Z., Pasquini S., and Ertl H.C. Effect of passive immunization or maternally transferred immunity on the antibody response to a genetic vaccine to rabies virus. J Virol 72 3 (1998) 1790-1796
241. Bembridge G.P., Rodriguez N., Garcia-Beato R., Nicolson C., Melero J.A., and Taylor G. DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammation. J Gen Virol 81 Pt 10 (2000) 2519-2523
242. Li X., Sambhara S., Li C.X., Ettorre L., Switzer I., Cates G., et al. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate. Virology 269 1 (2000) 54-65
243. Hancock G.E., Speelman D.J., Heers K., Bortell E., Smith J., and Cosco C. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J Virol 70 11 (1996) 7783-7791
244. Openshaw P.J., Clarke S.L., and Record F.M. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int Immunol 4 4 (1992) 493-500
245. Taylor G., Bruce C., Barbet A.F., Wyld S.G., and Thomas L.H. DNA vaccination against respiratory syncytial virus in young calves. Vaccine 23 10 (2005) 1242-1250
246. Tree J.A., Bembridge G., Hou S., Taylor G., Fashola-Stone E., Melero J., et al. An assessment of different DNA delivery systems for protection against respiratory syncytial virus infection in the murine model: gene-gun delivery induces IgG in the lung. Vaccine 22 19 (2004) 2438-2443
247. Bembridge G.P., Rodriguez N., Garcia-Beato R., Nicolson C., Melero J.A., and Taylor G. Respiratory syncytial virus infection of gene gun vaccinated mice induces Th2-driven pulmonary eosinophilia even in the absence of sensitisation to the fusion (F) or attachment (G) protein. Vaccine 19 9-10 (2000) 1038-1046
248. Hsu S.C., Obeid O.E., Collins M., Iqbal M., Chargelegue D., and Steward M.W. Protective cytotoxic T lymphocyte responses against paramyxoviruses induced by epitope-based DNA vaccines: involvement of IFN-gamma. Int Immunol 10 10 (1998) 1441-1447
249. Iqbal M., Lin W., Jabbal-Gill I., Davis S.S., Steward M.W., and Illum L. Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice. Vaccine 21 13-14 (2003) 1478-1485
250. Bartholdy C., Olszewska W., Stryhn A., Thomsen A.R., and Openshaw P.J. Gene-gun DNA vaccination aggravates respiratory syncytial virus-induced pneumonitis. J Gen Virol 85 Pt 10 (2004) 3017-3026